RxDoctor Payments Data

Thandar Aung, MD

Epilepsy · Pittsburgh, PANPI 1740539212

Payments from drug & device makers

What this record shows

DIXI Medical USA Corp accounts for 82.8% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2022 at $5,961 and has fallen 88.6% since, to $681 in 2025.

$13,098in general payments, 2019–2025

Across 29 payments — averaging $451.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • DIXI Medical USA Corp$11K
  • Neuropace, Inc.$1K
  • UCB, Inc.$573
  • SK Life Science, Inc.$211
  • Jazz Pharmaceuticals Inc.$191
  • Greenwich Biosciences, Inc.$109
  • plus $80 from 1 others

What the payments were for

  • Travel & lodging$7,58458%
  • Food & beverage$5,51442%

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,098 in reported general payments places this provider in the 75th percentile of 28 epilepsy providers in Pennsylvania.

See all epilepsy providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$6,594
Medicare patients
75
Services billed
92

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VimpatLacosamide22$22,043
XcopriCenobamate11$10,506
Lacosamide37$4,891
Levetiracetam75$2,258
Lamotrigine53$864
RivastigmineRivastigmine Tartrate12$624
Clobazam15$615
Carbidopa-LevodopaCarbidopa/Levodopa20$584
Zonisamide23$321
Pregabalin11$246
Oxcarbazepine12$208
Topiramate19$114
Pantoprazole Sodium13$86
Donepezil Hcl12$84
Carbidopa-Levodopa ErCarbidopa/Levodopa11$55

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
UCB, Inc.Vimpat$573$22,04322 claims
SK Life Science, Inc.Xcopri$211$10,50611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 28 epilepsy providers in Pennsylvania.

Other epilepsy in Pittsburgh

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →